Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

被引:29
|
作者
Kulozik, Felix [1 ]
Hasslacher, Christoph [1 ]
机构
[1] Diabet Inst Heidelberg, Landhausstr 25, D-69115 Heidelberg, Germany
关键词
diabetic nephropathy; renal insufficiency; insulin requirement; human insulin; insulin analogues; insulin glargin; insulin detemir; insulin lispro; insulin aspart;
D O I
10.1177/2042018813501188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In diabetic nephropathy the decline of renal function causes modifications of the insulin and carbohydrate metabolism resulting in changed insulin requirements. The aim of the present study was to identify potential differences in the requirements of human insulin and various insulin analogues in patients with type 1 diabetes mellitus and renal dysfunction. Methods: The insulin requirements of 346 patients with type 1 diabetes mellitus under everyday life circumstances were assessed in an observational study. Simultaneously, laboratory parameters were measured and the estimated glomerular filtration rate (eGFR) was calculated using the formula by Cockcroft-Gault. Medical history and concomitant medication were recorded. The insulin requirements of long-and short-acting insulin were tested for a relationship with the eGFR and laboratory parameters. Results: The dosage of long-acting human insulin did not show any relation to eGFR. In contrast, a strong positive relation between dosage and renal function was found for insulin glargine and insulin detemir. After classification according to renal function, the insulin dosage at eGFR less than 60 ml/min was 29.7% lower in glargine-treated and 27.3% lower in detemir-treated patients compared with eGFR greater than 90 ml/min. Considering the whole range of eGFR, short-acting human insulin did not show a relation with renal function. Only after classification according to renal function was a dose reduction found for human insulin at eGFR less than 60 ml/min. In contrast, requirements of insulin lispro were significantly related to eGFR over the whole range of eGFR. At eGFR less than 60 ml/min the insulin dosage was 32.6% lower than at eGFR greater than 90 ml/min. The requirements of insulin aspart did not show any association with the eGFR. Conclusions: Patients with type 1 diabetes mellitus show different insulin requirements according to the renal function depending on the applied insulin. This finding is essential for the adjustment of insulin therapy in patients with diabetic nephropathy to achieve balanced glycemic control. To determine the underlying mechanisms, further studies on the pharmacokinetics and pharmacodynamics of the different insulins in patients with diabetic nephropathy are needed.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
  • [1] Incidence of Diabetes Complications in Patients on Insulin Analogues Against Those on Human Insulin
    Gini, Rosa
    Roberto, Giuseppe
    Cipriani, Francesco
    Seghieri, Giuseppe
    Francesconi, Paolo
    Lapi, Francesco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 265 - 265
  • [2] Diabetes, insulin, insulin analogues, and cancer
    Muessig, K.
    Staiger, H.
    Kantartzis, K.
    Fritsche, A.
    Kanz, L.
    Haering, H.-U.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (18) : 924 - 929
  • [3] Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
    Hemkens, L. G.
    Grouven, U.
    Bender, R.
    Guenster, C.
    Gutschmidt, S.
    Selke, G. W.
    Sawicki, P. T.
    DIABETOLOGIA, 2009, 52 (09) : 1732 - 1744
  • [4] Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
    Siebenhofer, A.
    Plank, J.
    Berghold, A.
    Jeitler, K.
    Horvath, K.
    Narath, M.
    Gfrerer, R.
    Pieber, T. R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [5] Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
    L. G. Hemkens
    U. Grouven
    R. Bender
    C. Günster
    S. Gutschmidt
    G. W. Selke
    P. T. Sawicki
    Diabetologia, 2009, 52 : 1732 - 1744
  • [6] Measurement of insulin analogues in parallel to endogeneous insulin in patients with diabetes mellitus
    Pfuetzner, Andreas
    Nissum, Mikkel
    Safinowski, Michael
    Sukop, Ute
    Forst, Thomas
    Eckerskorn, Christoph
    DIABETES, 2008, 57 : A152 - A152
  • [7] Insulin Analogues Insulin Glargine and Insulin Glulisine in Type 1 Diabetes
    Schreiber, S. A.
    Fiesselmann, A.
    Bornstein, S. R.
    Landgraf, W.
    DIABETES STOFFWECHSEL UND HERZ, 2011, 20 (02): : 69 - 77
  • [8] Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
    K. Hermansen
    P. Fontaine
    K. K. Kukolja
    V. Peterkova
    G. Leth
    M.-A. Gall
    Diabetologia, 2004, 47 : 622 - 629
  • [9] Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
    Hermansen, K
    Fontaine, P
    Kukolja, KK
    Peterkova, V
    Leth, G
    Gall, MA
    DIABETOLOGIA, 2004, 47 (04) : 622 - 629
  • [10] Short-acting insulin analogues vs. human insulin for diabetes
    Schooff, M
    Ehlers, K
    AMERICAN FAMILY PHYSICIAN, 2005, 72 (05) : 805 - 807